Rocket Pharmaceuticals, Inc. Tax Withholding Paid on Stock Awards
Rocket Pharmaceuticals, Inc. (RCKT) reported Tax Withholding Paid on Stock Awards of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2023-02-28
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2021-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2020-09-30 was $76.00K.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2020 was $614.00K, a 78.49% increase from fiscal 2019.
- Rocket Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2019 was $344.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $76.00K derived: sum of 2 quarters · filed 2023-02-28 | $614.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $614.00K 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $538.00K 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $344.00K derived: sum of 2 quarters · filed 2022-02-28 | $344.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $16.00K derived: sum of 2 quarters · filed 2018-03-07 | $16.00K 10-K · filed 2018-03-07 | |
| 2017-09-30 | $16.00K 10-Q · filed 2017-11-08 | $16.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |